BeiGene Ltd.

NASDAQ: BGNE · Real-Time Price · USD
184.71
0.90 (0.49%)
At close: Dec 31, 2024, 10:00 PM

BeiGene Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
3.81B 2.46B 1.42B 1.18B
Cost of Revenue
594.09M 379.92M 1.93B 1.62B
Gross Profit
3.22B 2.08B -511.06M -447.86M
Operating Income
-568.2M -1.21B -1.79B -1.44B
Interest Income
47.84M 74.01M 52.48M 15.76M
Pretax Income
-533M -825.84M -1.96B -1.44B
Net Income
-644.79M -881.71M -2B -1.41B
Selling & General & Admin
1.83B 1.5B 1.28B 990.12M
Research & Development
1.95B 1.78B 1.64B 1.46B
Other Expenses
n/a 3.5M 751K 750K
Operating Expenses
3.78B 3.29B 1.28B 990.87M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
4.38B 3.67B 3.21B 2.62B
Income Tax Expense
111.78M 55.87M 42.78M -25.23M
Shares Outstanding (Basic)
104.78M 104.18M 103.13M 92.79M
Shares Outstanding (Diluted)
104.78M 104.18M 103.13M 92.79M
EPS (Basic)
-79.43 -8.45 -19.37 -15.21
EPS (Diluted)
-6.11 -8.45 -19.37 -15.21
EBITDA
-396.44M -1.12B -1.72B -1.39B
EBIT
-568.2M -1.21B -1.79B -1.44B
Depreciation & Amortization
171.76M 87.67M 66.28M 46.46M